Skip to content
Esta página está disponible en españolCambiar →
GestorLensSign up

MiniMed Group (MMED): which funds own it

Health Care →(by SIC code, unreviewed)Data as of Jun 30, 2026 (Q2 2026) · updated on Nov 5, 2026

A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.

Follow MMED for free
Share

Sections with a free account

1 concentrated manager holds it with a median weight of 0.5%.

Who owns MiniMed Group?

Holders reporting more than 5% of the shares to the SEC (Schedules 13D/13G): Capital Ventures International, 7.8% (13G filed Oct 22, 2026). As of Jun 30, 2026, the largest holders reported on Form 13F were Massachusetts Financial Services (3.0% of the shares), Millennium Management (1.1%) and Citadel Advisors (1.0%).

Which institutions hold the most MiniMed Group shares?

Per Form 13F filings as of Jun 30, 2026, as a share of all shares outstanding:

  1. 1. Massachusetts Financial Services: 3.0%
  2. 2. Millennium Management: 1.1%
  3. 3. Citadel Advisors: 1.0%
  4. 4. Longaeva Partners: 1.0%
  5. 5. Sessa Capital IM: 0.7%
  6. 6. BlackRock: 0.7%
  7. 7. Norges Bank: 0.7%
  8. 8. Rock Springs Capital Management: 0.5%
  9. 9. ExodusPoint Capital Management: 0.5%
  10. 10. FMR: 0.4%

How much of MiniMed Group do institutions own?

The 98 institutions that file 13F reported 13.3% of the shares as of Jun 30, 2026.

Sources:13G by Capital Ventures International (Oct 22, 2026) ↗All of the company's proxy statements on EDGAR ↗

13F percentages divide the shares each institution reports by the shares outstanding on the cover of the company's latest report before the quarter end (Jun 19, 2026). Entities of the same group file separately and are not added up. We hold 13D and 13G filings made since Dec 23, 2024: a holder above 5% that has not filed since then does not appear here.

MiniMed Group revenue

MiniMed Group reported annual revenue of $3.10 billion for fiscal year 2026 (year ended April 24, 2026), according to its Form 10-K filed with the SEC (XBRL data).

Concentrated managers
1
All 13F: 98
Consensus
—
No score: it needs 5 or more concentrated managers
Price at Jun 30, 2026 (per 13F)
$14.95
+0.2% in the quarter · reported value ÷ shares, not the quote · See current quote ↗

Quarter flow (concentrated managers)

Change in managers (1 → 1): 0 opened · 0 exited = 0

Net flow in the quarter: $0K (0 shares) · bought $0 and sold $0Shares concentrated managers added minus those they cut, valued at the 13F quarter-end implied price, not each trade's price. It is a different measure from the change in managers: the two can have opposite signs.

Concentrated managers holding it

Up to 15, sorted by position value. The percentage is the weight in each manager's portfolio.

Largest holders of MMED (all 13F filers)

The 10 13F filers with the most shares as of Jun 30, 2026, whatever their type (index firms usually come first). “Change”: shares added or cut versus the previous quarter, split-adjusted; “no data” = there is no comparable portfolio for the previous quarter (no filing, or a filing with its holdings under confidential treatment). “% of the company” only where shares outstanding are up to date. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. With a free account: the top 25, the largest buyers and the largest sellers.

Held by institutions (13F)

Institutions (13F): 13.3% of the shares · top 10: 9.6% · in index firms: 12.3% of the institutional total

Shares reported by the 98 13F filers as of Jun 30, 2026, divided by the shares outstanding on the cover of the company's latest report (Jun 19, 2026). It is not all institutional ownership: only managers above $100M file a 13F, and it excludes short positions. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. We only publish it where the figure is credible: not for ADRs, companies with more than one share class or stale shares-outstanding data.

Fundamentals

12-month figures to Jul 31, 2026 · balance sheet as of Jul 31, 2026.

Profitability
Operating margin
-5.3%
Net margin
-9.7%
ROE
-8.7%
Growth
Revenue (TTM)
$3.2 bn
Revenue growth
—
Net income (TTM)
$-314M
Balance sheet
Net debt / EBITDA
—
Free cash flow (TTM)
$-316M
Quality vs sector
—

This company's sector comes from its SIC code, unreviewed, or has too few comparable companies: we do not compare it with its sector.

Figures from the statements the company filed with the SEC (10-K, 10-Q). Free cash flow = operating cash flow − capital expenditures; empty if the company does not report capex. “Quality vs sector”: 0 to 100, the average of its percentiles in ROE, operating margin, free-cash-flow margin, revenue and earnings growth and net debt / EBITDA (at least 3 needed) against companies in its sector above $300M. How each figure is calculated

Earnings quality and debt

Operating cash flow ÷ net income (12 months)
no datanot calculated with negative net income
Interest coverage (operating income ÷ interest)
no data
Debt due within 12 months
no data

From the figures the company filed with the SEC. Cash flow over net income near or above 1 means earnings are collected in cash; far below, that part is accounting. Coverage says how many times operating income pays the latest fiscal year's interest. Maturities come from the debt note of the latest annual report, counted from its closing date. “No data” never means zero.

Insiders (Form 4)

Officers and directors who bought (6 m)
no data
Amount (6 m)
no data
CEO/CFO bought (12 m)
No

Open-market purchases, excluding 10b5-1 plans. Officers and directors only; joint filers of the same purchase count as one. 10% owners with no role are shown separately. 0 = nobody bought; “no data” = we do not have its Form 4 filings.

Each of the company's Form 4 filings, on EDGAR ↗Latest trades, with date and filing →

Above 5% (13D/13G)

Disclosed stakes, with their amendments. A filing is not always a purchase: there are also reductions and changes of filing entity.

This list may be incomplete: we hold 13D and 13G filings made since Dec 23, 2024. A holder above 5% that has not filed anything since then is not shown here.

  • Capital Ventures International7.8%13Gfiling ↗Event: Oct 15, 2026 · filed: Oct 22, 2026
  • Medtronicfell below 5%13G · amendmentfiling ↗Event: Oct 15, 2026 · filed: Oct 16, 2026
  • Medtronic90%13Gfiling ↗Event: Mar 31, 2026 · filed: May 6, 2026

Above 5% over time (13D/13G)

Each holder with its filings in order. History since December 2024.

Flagged material events (8-K)

  • Oct 16, 2026Routinefiling ↗

    Change in directors or officers (Item 5.02)

    «MiniMed Completes Separation from Medtronic»

  • Aug 5, 2026Routinefiling ↗

    Change in directors or officers (Item 5.02)

  • Jun 29, 2026Routinefiling ↗

    Change in directors or officers (Item 5.02)

  • May 18, 2026Routinefiling ↗

    Change in directors or officers (Item 5.02)

  • Mar 27, 2026Routinefiling ↗

    Change in directors or officers (Item 5.02)

  • Mar 9, 2026Routinefiling ↗

    Unregistered sale of equity securities (Item 3.02)

  • Mar 9, 2026Routinefiling ↗

    Change in directors or officers (Item 5.02)

Alert items the company itself flagged in its 8-K filings with the SEC, most serious first. It is the form's label, with no interpretation from us: Item 5.02 covers routine appointments as well as a chief executive's departure; open the filing. The quoted headline is the original press release's.

All material events (8-K)

Earnings, agreements, financing, management changes and announcements from the last year, with a filter by type and a link to each filing.

Other Health Care stocks in managers' portfolios

Same sector and a similar number of concentrated managers holding them. It is a list to keep exploring, not a recommendation.

All of Health Care →

Follow MMED for free

If someone reports a 5%+ stake, we email you (if you turn it on). And when you come back, see whether concentrated managers got in or out. No credit card.

Follow MMED